%0 Journal Article
%T Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab
%A Paolo Nuciforo
%J SCIE-indexed Journal
%D 2016
%R 10.21037/9524
%X Trastuzumab in breast cancer exemplifies the paradigm of successful targeted therapy. This anti-HER2 monoclonal antibody reduces the risk of recurrence by half when combined with standard chemotherapy (1-3). Its target¡ªHER2¡ªis overexpressed in 20% of breast cancers and testing for HER2 positivity is the sine qua non for anti-HER2 therapies. Consensus guidelines have been developed for the definition of HER2-positive (HER2+) tumors. HER2 protein expression has to be 3+ by immunohistochemistry (IHC) or the gene has to be amplified by fluorescence (FISH) or chromogenic (CISH) in situ hybridization (4)
%U http://tcr.amegroups.com/article/view/9524/html